SIEMENS

  Change

Viva-E® Drug Testing System

 
  • Site Explorer
  • Contact
  • Laboratory Diagnostics
  • Products
    • Automation
    • Chemistry/Immunoassay
    • Informatics
    • Hemostasis
    • Hematology
    • Microbiology
    • Molecular Diagnostics
    • Diabetes and Urinalysis
    • Blood Gas
    • Integrated Diagnostics
  • Chemistry/Immunoassay
    • Integrated Systems
    • Immunoassay Systems
    • Clinical Chemistry Systems
    • Specialty Immunoassay Systems
  • Specialty Immunoassay Systems
    • Stratus® CS Acute Care™ Diagnostic System
    • BN ProSpec® System
    • BN™ II System
    • V-Twin® Drug Testing System
    • Viva-E® Drug Testing System
    • Viva-Jr® Drug Testing System
    • Quadriga BeFree™ System
    • BEP® III System
    • BEP 2000 Advance® System
    • Protis® Result Interpretation Software
  • Viva-E® Drug Testing System

Viva-E® Drug Testing System

The system features Syva® Emit® tests in a state-of-the art instrument.

The Viva-E® Drug Testing System features Syva® Emit® tests in a state-of-the art instrument that's "just right" for your testing needs.

Only the Viva-E® combines a complete menu for drugs of abuse testing, therapeutic drug monitoring, immuno-
suppressive drug monitoring and sample validity testing on a single bench top analyzer, plus WinTox® Data Manager*.

The Viva-E® improves the quality and efficiency of your program whether you are currently performing onsite testing or sending samples to a reference laboratory.
Over 30 tests for drugs of abuse, validity, therapeutic and immunosuppressive drugs.

The commitment and expertise of a seasoned group of specialists has made Siemens Syva® product line the industry leader in drugs of abuse testing for over 40 years.

* Available in the US only.

/siemens/en_GLOBAL/gg_diag_FBAs/images/product_images/Chemistry_Immunoassay/Speciality_Immunoassay_Systems/viva_e_drug_testing_h5.jpg

Customer Care

  • Education
  Close  



  Close  



© Siemens Healthcare Diagnostics Inc. 2007-2008. All rights reserved | Corporate Information | Privacy Statement | Terms of Use
  • Print this page
  • Email this page